[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lineage Cell Therapeutics Inc (LCTX)

Lineage Cell Therapeutics Inc (LCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 388,577
  • Shares Outstanding, K 249,088
  • Annual Sales, $ 14,560 K
  • Annual Income, $ -63,530 K
  • EBIT $ -22 M
  • EBITDA $ -6 M
  • 60-Month Beta 1.79
  • Price/Sales 27.89
  • Price/Cash Flow N/A
  • Price/Book 8.66

Options Overview Details

View History
  • Implied Volatility 135.67% (+33.68%)
  • Historical Volatility 48.73%
  • IV Percentile 29%
  • IV Rank 12.89%
  • IV High 516.69% on 06/12/25
  • IV Low 79.27% on 04/21/26
  • Expected Move (DTE 21) 0.2465 (15.85%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 103
  • Volume Avg (30-Day) 238
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 9,069
  • Open Int (30-Day) 8,027
  • Expected Range 1.3085 to 1.8015

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.02
  • Number of Estimates 2
  • High Estimate $-0.01
  • Low Estimate $-0.03
  • Prior Year $-0.02
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4500 +6.55%
on 04/13/26
1.7500 -11.71%
on 04/17/26
+0.0650 (+4.39%)
since 03/24/26
3-Month
1.4200 +8.80%
on 03/24/26
1.9850 -22.17%
on 03/02/26
-0.0650 (-4.04%)
since 01/23/26
52-Week
0.4250 +263.53%
on 05/07/25
2.0900 -26.08%
on 11/03/25
+1.0467 (+210.05%)
since 04/24/25

Most Recent Stories

More News
Lineage Announces Formation of Scientific Advisory Board

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions,...

LCTX : 1.5500 (-0.64%)
Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

New Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturing Expertise Fuchs Endothelial Corneal Dystrophy (FECD)...

LCTX : 1.5500 (-0.64%)
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Positive RG6501 (OpRegen ® Cell Therapy) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 ...

LCTX : 1.5500 (-0.64%)
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or “off the shelf”, cell therapies for serious medical conditions,...

LCTX : 1.5500 (-0.64%)
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions,...

LCTX : 1.5500 (-0.64%)
Lineage Cell Therapeutics Issues Letter to Stockholders

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions,...

LCTX : 1.5500 (-0.64%)
Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Positive RG6501 (OpRegen ® ) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 ...

LCTX : 1.5500 (-0.64%)
Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or “off the shelf”, cell therapies for serious medical conditions,...

LCTX : 1.5500 (-0.64%)
Anti-Aging Market Surges as $101M Competition Drives Demographic Revolution

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The global longevity biotech market exploded from $27.15 billion in 2024 toward $46.61 billion by 2033...

LXRX : 1.6550 (-1.49%)
AVAI : 0.3400 (+11.48%)
LCTX : 1.5500 (-0.64%)
ARQT : 23.08 (+0.96%)
AMGN : 344.51 (-1.18%)
Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes

Initial Program Focus Will Be On Addressing Manufacturing Scale

LCTX : 1.5500 (-0.64%)

Business Summary

Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company. It focuses on developing and commercializing therapies for the treatment of degenerative diseases primarily in the United States and internationally. The company's lead product candidates include OpRegen, OPC1 and VAC2 which are...

See More

Key Turning Points

3rd Resistance Point 1.7450
2nd Resistance Point 1.7000
1st Resistance Point 1.6300
Last Price 1.5500
1st Support Level 1.5150
2nd Support Level 1.4700
3rd Support Level 1.4000

See More

52-Week High 2.0900
Last Price 1.5500
Fibonacci 61.8% 1.4540
Fibonacci 50% 1.2575
Fibonacci 38.2% 1.0610
52-Week Low 0.4250

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.